Literature DB >> 25084760

Cholesterol 24S-Hydroxylase Overexpression Inhibits the Liver X Receptor (LXR) Pathway by Activating Small Guanosine Triphosphate-Binding Proteins (sGTPases) in Neuronal Cells.

Miguel Moutinho1, Maria João Nunes, Anita Q Gomes, Maria João Gama, Angel Cedazo-Minguez, Cecília M P Rodrigues, Ingemar Björkhem, Elsa Rodrigues.   

Abstract

The neuronal-specific cholesterol 24S-hydroxylase (CYP46A1) is important for brain cholesterol elimination. Cyp46a1 null mice exhibit severe deficiencies in learning and hippocampal long-term potentiation, suggested to be caused by a decrease in isoprenoid intermediates of the mevalonate pathway. Conversely, transgenic mice overexpressing CYP46A1 show an improved cognitive function. These results raised the question of whether CYP46A1 expression can modulate the activity of proteins that are crucial for neuronal function, namely of isoprenylated small guanosine triphosphate-binding proteins (sGTPases). Our results show that CYP46A1 overexpression in SH-SY5Y neuroblastoma cells and in primary cultures of rat cortical neurons leads to an increase in 3-hydroxy-3-methyl-glutaryl-CoA reductase activity and to an overall increase in membrane levels of RhoA, Rac1, Cdc42 and Rab8. This increase is accompanied by a specific increase in RhoA activation. Interestingly, treatment with lovastatin or a geranylgeranyltransferase-I inhibitor abolished the CYP46A1 effect. The CYP46A1-mediated increase in sGTPases membrane abundance was confirmed in vivo, in membrane fractions obtained from transgenic mice overexpressing this enzyme. Moreover, CYP46A1 overexpression leads to a decrease in the liver X receptor (LXR) transcriptional activity and in the mRNA levels of ATP-binding cassette transporter 1, sub-family A, member 1 and apolipoprotein E. This effect was abolished by inhibition of prenylation or by co-transfection of a RhoA dominant-negative mutant. Our results suggest a novel regulatory axis in neurons; under conditions of membrane cholesterol reduction by increased CYP46A1 expression, neurons increase isoprenoid synthesis and sGTPase prenylation. This leads to a reduction in LXR activity, and consequently to a decrease in the expression of LXR target genes.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25084760     DOI: 10.1007/s12035-014-8828-0

Source DB:  PubMed          Journal:  Mol Neurobiol        ISSN: 0893-7648            Impact factor:   5.590


  59 in total

1.  Brain cholesterol turnover required for geranylgeraniol production and learning in mice.

Authors:  Tiina J Kotti; Denise M O Ramirez; Brad E Pfeiffer; Kimberly M Huber; David W Russell
Journal:  Proc Natl Acad Sci U S A       Date:  2006-02-27       Impact factor: 11.205

Review 2.  Post-translational modifications and regulation of the RAS superfamily of GTPases as anticancer targets.

Authors:  Panagiotis A Konstantinopoulos; Michalis V Karamouzis; Athanasios G Papavassiliou
Journal:  Nat Rev Drug Discov       Date:  2007-07       Impact factor: 84.694

3.  Regulation of macrophage cholesterol efflux through hydroxymethylglutaryl-CoA reductase inhibition: a role for RhoA in ABCA1-mediated cholesterol efflux.

Authors:  Carmen A Argmann; Jane Y Edwards; Cynthia G Sawyez; Caroline H O'Neil; Robert A Hegele; J Geoffrey Pickering; Murray W Huff
Journal:  J Biol Chem       Date:  2005-04-06       Impact factor: 5.157

Review 4.  Rho and Ras GTPases in axon growth, guidance, and branching.

Authors:  Alan Hall; Giovanna Lalli
Journal:  Cold Spring Harb Perspect Biol       Date:  2010-02       Impact factor: 10.005

5.  Cholesterol loss during glutamate-mediated excitotoxicity.

Authors:  Alejandro O Sodero; Joris Vriens; Debapriya Ghosh; David Stegner; Anna Brachet; Marta Pallotto; Marco Sassoè-Pognetto; Jos F Brouwers; J Bernd Helms; Bernhard Nieswandt; Thomas Voets; Carlos G Dotti
Journal:  EMBO J       Date:  2012-02-17       Impact factor: 11.598

6.  SNAREs are concentrated in cholesterol-dependent clusters that define docking and fusion sites for exocytosis.

Authors:  T Lang; D Bruns; D Wenzel; D Riedel; P Holroyd; C Thiele; R Jahn
Journal:  EMBO J       Date:  2001-05-01       Impact factor: 11.598

7.  Regionally specific neuronal expression of human APOE gene in transgenic mice.

Authors:  P T Xu; J R Gilbert; H L Qiu; T Rothrock-Christian; D L Settles; A D Roses; D E Schmechel
Journal:  Neurosci Lett       Date:  1998-04-24       Impact factor: 3.046

8.  Inhibition of Rho GTPases with protein prenyltransferase inhibitors prevents leukocyte recruitment to the central nervous system and attenuates clinical signs of disease in an animal model of multiple sclerosis.

Authors:  John Greenwood; Peter Adamson; Claire E Walters; Gareth Pryce; Deborah J R Hankey; Said M Sebti; Andrew D Hamilton; David Baker
Journal:  J Immunol       Date:  2002-04-15       Impact factor: 5.422

9.  Ras inhibition by FTS attenuates brain tumor growth in mice by direct antitumor activity and enhanced reactivity of cytotoxic lymphocytes.

Authors:  Elizabeta Aizman; Adi Mor; Ayelet Levy; Jacob George; Yoel Kloog
Journal:  Oncotarget       Date:  2012-02

10.  Inhibition of rho kinase enhances survival of dopaminergic neurons and attenuates axonal loss in a mouse model of Parkinson's disease.

Authors:  Lars Tönges; Tobias Frank; Lars Tatenhorst; Kim A Saal; Jan C Koch; Éva M Szego; Mathias Bähr; Jochen H Weishaupt; Paul Lingor
Journal:  Brain       Date:  2012-10-19       Impact factor: 13.501

View more
  10 in total

1.  CYP46A1 Activation by Efavirenz Leads to Behavioral Improvement without Significant Changes in Amyloid Plaque Load in the Brain of 5XFAD Mice.

Authors:  Alexey M Petrov; Morrie Lam; Natalia Mast; Jean Moon; Yong Li; Erin Maxfield; Irina A Pikuleva
Journal:  Neurotherapeutics       Date:  2019-07       Impact factor: 7.620

2.  Targeting cytochrome P450 46A1 and brain cholesterol 24-hydroxylation to treat neurodegenerative diseases.

Authors:  Irina A Pikuleva
Journal:  Explor Neuroprotective Ther       Date:  2021-12-30

Review 3.  LXR Regulation of Brain Cholesterol: From Development to Disease.

Authors:  Rebecca Courtney; Gary E Landreth
Journal:  Trends Endocrinol Metab       Date:  2016-04-21       Impact factor: 12.015

4.  The key genes, phosphoproteins, processes, and pathways affected by efavirenz-activated CYP46A1 in the amyloid-decreasing paradigm of efavirenz treatment.

Authors:  Alexey M Petrov; Natalia Mast; Yong Li; Irina A Pikuleva
Journal:  FASEB J       Date:  2019-05-07       Impact factor: 5.834

5.  Role of Liver X Receptor in AD Pathophysiology.

Authors:  Adrián G Sandoval-Hernández; Luna Buitrago; Herman Moreno; Gloria Patricia Cardona-Gómez; Gonzalo Arboleda
Journal:  PLoS One       Date:  2015-12-31       Impact factor: 3.240

6.  Neuronal cholesterol metabolism increases dendritic outgrowth and synaptic markers via a concerted action of GGTase-I and Trk.

Authors:  Miguel Moutinho; Maria João Nunes; Jorge C Correia; Maria João Gama; Margarida Castro-Caldas; Angel Cedazo-Minguez; Cecília M P Rodrigues; Ingemar Björkhem; Jorge L Ruas; Elsa Rodrigues
Journal:  Sci Rep       Date:  2016-08-05       Impact factor: 4.379

Review 7.  Defects of Nutrient Signaling and Autophagy in Neurodegeneration.

Authors:  Jon Ondaro; Haizea Hernandez-Eguiazu; Maddi Garciandia-Arcelus; Raúl Loera-Valencia; Laura Rodriguez-Gómez; Andrés Jiménez-Zúñiga; Julen Goikolea; Patricia Rodriguez-Rodriguez; Javier Ruiz-Martinez; Fermín Moreno; Adolfo Lopez de Munain; Ian James Holt; Francisco Javier Gil-Bea; Gorka Gereñu
Journal:  Front Cell Dev Biol       Date:  2022-03-28

Review 8.  Altered Cholesterol Homeostasis in Huntington's Disease.

Authors:  Radhia Kacher; Coline Mounier; Jocelyne Caboche; Sandrine Betuing
Journal:  Front Aging Neurosci       Date:  2022-04-19       Impact factor: 5.750

9.  Transcriptional and post-translational changes in the brain of mice deficient in cholesterol removal mediated by cytochrome P450 46A1 (CYP46A1).

Authors:  Natalia Mast; Joseph B Lin; Kyle W Anderson; Ingemar Bjorkhem; Irina A Pikuleva
Journal:  PLoS One       Date:  2017-10-26       Impact factor: 3.240

10.  LXRβ controls glioblastoma cell growth, lipid balance, and immune modulation independently of ABCA1.

Authors:  Deven Patel; Fahim Ahmad; Diane M Kambach; Qian Sun; Alan S Halim; Tamalee Kramp; Kevin A Camphausen; Jayne M Stommel
Journal:  Sci Rep       Date:  2019-10-29       Impact factor: 4.379

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.